XLV241025C154000
- 0.58
- +0.10+20.83%
The Health Care Select Sector SPDR® Fund Newsroom
Buy ahead of time in 2016? Benefiting from the 'Trump trade,' assets are outpacing the market, but this time 'it's somewhat different.'
Republican presidential candidate Trump's polls are reversing, and the 'winning odds' are gradually increasing. A Merrill Lynch strategist pointed out that investors seem to be rushing to allocate to symbols that performed well after Trump's victory in 2016. What inspiration does this have for investment?
Earnings Week Ahead: TSLA, GE, GM, KO, PM, LUV, AAL, VZ, T and More
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Activist Investor Starboard Takes Stake in Kenvue - WSJ
Three Events That Shook Health Insurers This Week
Over 60% of Companies That Reported Earnings This Week Beat EPS and Revenue Estimates - Earnings Scorecard
AbbVie Says Latest FDA Approval Expands Botox Use Beyond Face
Shares of Surgical Tool and Medical Instrument Stocks Are Trading Higher in Sympathy With Intuitive Surgical, Which Gained on Strong Q3 Earnings.
Tyra Raised to Buy by BofA Ahead of TYRA-300 Data Readout
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment
Stocks Rise, Netflix Soars To Record Highs, Oil Falls Below $70, Gold Miners Rally: What's Driving Markets Friday?
AbbVie Analyst Ratings
Johnson & Johnson Unusual Options Activity
Elevance, CVS, UnitedHealth Struggle With Rising Medical Costs After COVID-19 Medicaid Policy Ends
Shares of Health Insurance Stocks Are Trading Lower Following Recent Weak Earnings and Guidance From Multiple Companies in the Sector. CVS Fell on Friday Amid a CEO Change and Weak Guidance.
Behind the Scenes of Eli Lilly's Latest Options Trends
Oppenheimer Buy-rated Ideas: BSX, MDT, and One Hold: CYTK
UnitedHealth Group Analyst Ratings